Susquehanna Fundamental Investments’s Quince Therapeutics QNCX Stock Holding History

Susquehanna Fundamental Investments’s Portfolio QNCX Stock Details QNCX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-112	Closed	-$34.8K	–	830
2023 Q1	$34.8K	Hold	112	–	–	﹤0.01%	929
2022 Q4	$14.2K	Sell	112 -23	-17%	-$3.85K	﹤0.01%	1163
2022 Q3	$36K	Buy	+135	New	+$51.4K	﹤0.01%	1383
2021 Q4	–	Sell	-70	Closed	-$1.29M	–	1710
2021 Q3	$1.29M	Buy	70 +33	+89%	+$525K	0.02%	760
2021 Q2	$396K	Buy	+37	New	+$310K	0.01%	1258
2020 Q4	–	Sell	-86	Closed	-$859K	–	1583
2020 Q3	$859K	Buy	86 +39	+83%	+$355K	0.03%	691
2020 Q2	$439K	Buy	+47	New	+$431K	0.02%	647

Other funds holding QNCX

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

ECG

EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

KAM

Knightsbridge Asset Management Newport Beach, California $743M AUM 28.33% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna Fundamental Investments's QNCX Position: Q2 2023 in Review

Susquehanna Fundamental Investments sold out of Quince Therapeutics (QNCX) in Q2 2023, closing a stake of 112 shares — an estimated $34.8K sold.

Susquehanna Fundamental Investments first reported a position in QNCX in Q2 2020 and held it in 7 quarters. The position peaked at $1.29M in Q3 2021. 38 funds tracked by Wall St. Rank hold QNCX as of Q2 2023.

Susquehanna Fundamental Investments reported no remaining Quince Therapeutics position as of Q2 2023 after selling out during the quarter.
Susquehanna Fundamental Investments sold 112 Quince Therapeutics shares in Q2 2023, an estimated $34.8K.
Susquehanna Fundamental Investments first reported a position in Quince Therapeutics in Q2 2020 and held it in 7 quarters.
Susquehanna Fundamental Investments's Quince Therapeutics position peaked at $1.29M in Q3 2021.
38 funds tracked by Wall St. Rank held Quince Therapeutics as of Q2 2023.

Based on Susquehanna Fundamental Investments's 13F filing for Q2 2023, filed 11 Aug 2023.